Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Nozomi Oikawa and Masafumi Seki
To determine the differences in the clinical features of hospitalized elderly patients with influenza between the A (H1N1) pdm09 and the A (H3N2)-dominant seasons, 12 adult patients (mean age, 76.5 years) with influenza who were hospitalized during the 2015-2016 A (H1N1) pdm09-dominant season were compared with 26 adult patients (mean age, 82.5 years) with influenza who were hospitalized during the 2016-2017 A (H3N2)-dominant season. Compared with the A (H3N2)-dominant 2016-2017 season, the A (H1N1) pdm09-dominant 2015-2016 season had fewer non-survivors, but had significantly fewer patients who required oxygenation/respirator support and intravenous anti-influenza agents, such as peramivir. Among the severe patients who received oxygenation/respirator support, the outcomes were better in the A (H3N2)-dominant 2016-2017 season than in the A (H1N1) pdm09-dominant 2015-2016 season. The pneumonia types and detected bacteria did not differ between the two seasons, but the use of sulbactam/ampicillin was more frequent in the A (H1N1) pdm09-dominant 2015-2016 season than in the A (H3N2)-dominant 2016-2017 season. These data suggest that peramivir treatment and oxygenation/respirator support, but not sulbactam/ampicillin administration, may improve the outcome of severe elderly patients hospitalized for influenza, especially the A (H3N2) type.